GlaxoSmithKline plc And Its Drive For Growth

GlaxoSmithKline plc (LON: GSK) looks enticing with a steady dividend and plans to corner the malaria vaccine market.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline

The big-cap pharmaceuticals have been taking hits to their revenue as patents for a number of the biggest-selling drugs expire. This has led to investors questioning whether the likes of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) can maintain their generous dividend payouts. What’s going to drive their future revenue?

Fundamental to this is a reinvigorated drugs pipeline. GlaxoSmithKline has been dedicating time, cash and attention to pipeline development, which should bear fruit in the future.

Much of the company’s revenue comes from its vaccine portfolio, contributing $4.1 billion for the first nine months of 2013, or 16% of total revenue. The aim is to build a stronger vaccine portfolio and to do this the company is developing new molecules and enhancing the efficiency of its current vaccines.

Investing for the future

Good quality R&D is crucial, and while full of challenges, can’t be overlooked. Some analysts have stated that investment in research is an inefficient way to use a company’s money. Given that research is often unsuccessful, these analysts believe that ‘in-licencing’ is more efficient, which is bulking up the pipeline through outside sources.

True, R&D is expensive and investors in dividend stocks like to see a massive cash flow maintained to cover payouts. My belief is that that is short-termist. If you invest you’re investing for the future, which isn’t three to six months but five or more years. Long term you’ll reap the rewards.

New opportunities

GlaxoSmithKline has successfully developed the world’s first malaria vaccine — RTS,S — in collaboration with Agenus. To date it has invested $350 million and is planning to invest another $260 million to develop RTS,S as a complete vaccine to prevent malaria in young children and infants.

Now GlaxoSmithKline doesn’t set itself a fixed R&D budget. Instead of a budget, to be mindlessly tossed away, it views R&D much like you view your shares — as an investment. But were we to take its last published R&D numbers, for 2012, the $600,000 million spent on this new malaria drug doesn’t seem quite so eye-popping.

True it’s not an insubstantial amount, but realistically, purging the company’s R&D division won’t result in a windfall for shareholders (but there will be tears when the pipeline dries up).

For a chance to grab the majority of the malaria vaccine market the R&D expenditure makes sense. Again, look at it like an investment.

Valuation

Taking into account its strong drug portfolio, including its leading vaccines and the potential profitability of the malaria market, GlaxoSmithKline’s long-term growth prospects look good. Through a combination of pipeline production and cost cutting, earnings per share look set to go up.

It also has a dividend yield (4.5%) that outstrips the FTSE 100 average. Dividend growth has been robust over the past few years and the current yield is supported by a strong free cash flow.

Overall you get the best of both worlds. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

>Mark does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »